As a therapy for non-small-cell lung cancer (NSCLC), another study also supported the evaluation of SNX-5422, especially in cases where cancer was driven by c-Met amplification and mutated epidermal growth factor receptor (EGFR) forms that were resistant to EGFR inhibitors (Rice et al., 2009). The gene discussed is MET; the disease is non-small cell lung carcinoma.